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Eukaryotic cellular mRNA is believed to be synthesized exclusively by RNA polymerase II (pol II), whereas
pol I produces long rRNAs and pol III produces 5S rRNA, tRNA, and other small RNAs. To determine whether
this functional differentiation is obligatory, we examined the translational potential of an artificial pol III
transcript. The coding region of the human immunodeficiency virus type 1 tat gene was placed under the control
of a strong pol III promoter from the adenovirus type 2 VA RNAI gene. The resultant chimera, pVA-Tat, was
transcribed accurately in vivo and in vitro and gave rise to Tat protein, which transactivated a human
immunodeficiency virus-driven chloramphenicol acetyltransferase reporter construct in transfected HeLa
cells. pol III-specific mutations down-regulated VA-Tat RNA production in vivo and in vitro and dramatically
reduced chloramphenicol acetyltransferase transactivation. As expected for a pol III transcript, VA-Tat RNA
was not detectably capped at its 5* end or polyadenylated at its 3* end, but, like mRNA, it was associated with
polysomes in a salt-stable manner. Mutational analysis of a short open reading frame upstream of the
Tat-coding sequence implicates scanning in the initiation of VA-Tat RNA translation despite the absence of a
cap. In comparison with tatmRNA generated by pol II, VA-Tat RNA was present on smaller polysomes and was
apparently translated less efficiently, which is consistent with a relatively low initiation rate. Evidently, human
cells are capable of utilizing pol III transcripts as functional mRNAs, and neither a cap nor a poly(A) tail is
essential for translation, although they may be stimulatory. These findings raise the possibility that some
cellular mRNAs are made by pol I or pol III.
Eukaryotic RNA is synthesized by three distinct types of
cellular RNA polymerases, polymerase I (pol I), pol II, and pol
III. Although the three polymerases employ some common
transcription factors, they are recruited by distinct promoter
elements to different classes of genes. This results in a marked
degree of specialization such that individual classes of RNA
are produced by each polymerase: the large rRNAs are pro-
duced by pol I; mRNA and certain small RNAs are produced
by pol II; and tRNA, 5S rRNA, and certain other small RNAs
are produced by pol III. It seems that this discrimination is
respected absolutely and in all organisms; for example, no
cellular mRNA is known to be produced by any polymerase
other than pol II. This specialization with respect to RNA
products could reflect underlying characteristics of the poly-
merases that restrict the kinds of transcripts produced: the
intranuclear compartmentalization of pol I within the nucleo-
lus might be one example, and the tendency of pol III to
terminate transcription in runs of thymidine residues might
provide another. Alternatively, a functional limitation could be
imposed by some property of the transcript; for example, its
fate could be determined by a 59-terminal cap or 39-terminal
poly(A) tail. On the other hand, it is also possible that the
specialization, despite its universality, merely perpetuates
some archaic property of eukaryotes without any necessary
purpose in contemporary organisms.
Few attempts to resolve this issue experimentally have been
made, and the results to date have been inconclusive. Some
studies have examined the competence of pol I transcripts to
support protein synthesis. Fleischer and Grummt (14) reported
that simian virus 40 T antigen and bacterial chloramphenicol
acetyltransferase (CAT) can be expressed from a pol I pro-
moter in microinjected or transfected cells, at both transcrip-
tional and translational levels. The expression was a-amanitin
insensitive and unaffected by pol II enhancer elements, arguing
against the possibility that transcription actually arose from a
cryptic pol II promoter. On the other hand, Lopata et al. (40),
who used a similar pol I-CAT chimera, described the produc-
tion of aberrantly initiated transcripts which were polysome
associated and translated. The authentic transcript initiating at
the pol I initiation site was not polysome associated and was
unlikely to be translated. Whereas synthesis of the authentic
transcript was unresponsive to pol II enhancer elements, the
production of the aberrantly initiated transcripts and CAT
activity were stimulated by the pol II enhancer. These findings
called into question the earlier conclusion that pol I transcripts
can support protein synthesis in vivo. Further doubts were
added by the observation that herpesvirus thymidine kinase
RNA generated by pol I transcription was unstable, nonpolya-
denylated, and largely nucleolar (65). Similar controversy sur-
rounds mRNA synthesis by pol III. It has been reported that
b-globin transcripts generated by pol III were spliced and
polyadenylated (8) and that polyadenylated thymidine kinase
RNA was produced and transported efficiently into the cyto-
plasm from a chimeric gene under the control of a pol III
promoter (38), but these conclusions have also been disputed
(64).
One of the unique features of eukaryotic mRNA is the
presence of a characteristic 7-methyl guanosine (m7G) cap at
its 59 end, which is added during transcription, shortly after
elongation has commenced (30, 55, 60). Functions have been
attributed to the cap at numerous stages of gene expression: in
RNA stabilization, splicing, transport, and translation. The
scanning model of translational initiation proposes that ribo-
somal subunits bind to the mRNA 59 end and move along the
strand, in processes that are facilitated by the cap, until they
encounter the first translational initiation codon in a favorable
sequence context, whereupon translation is initiated (32). The
first-AUG rule holds for many natural and engineered mRNAs
and the presence of an upstream AUG or open reading frame
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(ORF) has deleterious effects on the translation of down-
stream ORFs, as predicted by the scanning hypothesis. Some
viral and cellular mRNAs do not follow this rule, however (66).
Their translation is not 59 end dependent, nor does it initiate at
the first AUG; instead, the ribosomes gain access to the ORF
through an internal ribosome entry site (IRES). A stimulatory
role in translational initiation has also been assigned to the 39
poly(A) tract (for a review, see reference 29), although the
existence of translationally active nonpolyadenylated mRNAs
argues that this modification is not indispensable.
In this study we examined the translational potential of a pol
III transcript to determine whether there is an obligatory link
between pol II transcription and mRNA function. The coding
region of the human immunodeficiency virus type 1 (HIV-1)
tat gene was placed under the control of a pol III promoter
derived from the adenovirus type 2 VA RNAI gene. The Tat-
coding sequence is short and lacks runs of thymidines which
constitute the termination signal for pol III transcription (5),
and the biological activity of the Tat protein can be assayed in
vivo by cotransfection with a reporter construct containing the
HIV-1 promoter which is transactivated by Tat. We show that
the chimeric plasmid pVA-Tat, thus constructed, was tran-
scribed in vivo and in vitro to generate the predicted RNA,
which was neither capped nor polyadenylated. Its transcription
was dependent on pol III-specific signals and was insensitive to
low concentrations of a-amanitin, as expected of a pol III
transcript. Like normal cellular mRNA, VA-Tat RNA, al-
though uncapped and nonpolyadenylated, was associated with
polysomes in a salt-stable manner. When cotransfected with
pHIV-CAT, pVA-Tat elicited a large increase in CAT activity,
showing that it generates functional mRNA which is trans-
lated. We conclude that active Tat can be generated by trans-
lation of an RNA produced by pol III. Although Tat expression
was weak in comparison with expression from a construct
driven by a strong pol II promoter (pCMV-Tat), these findings
imply that pol III transcripts can be transported properly
within the cell and assembled with translational components.
The relatively inefficient translation of VA-Tat RNA seems to
be due at least in part to an impediment to initiation, suggest-
ing that pol II transcripts may predominate in the mRNA
population because other transcripts are handicapped at vari-
ous stages in gene expression.
MATERIALS AND METHODS
Plasmid construction. pVA-Tat contains the first coding exon sequence of the
HIV-1 tat gene flanked by the promoter and termination sequences of the
adenovirus type 2 VA RNAI gene. It was constructed as follows: the XbaI-to-SalI
fragment from pMHIs6 (45), containing the VA RNA sequence, was ligated into
the equivalent sites in the polylinker sequence of the pUC119 to yield pVA-ls6.
The BamHI site in the polylinker in pVA-ls6 was deleted by cutting the plasmid
with KpnI and XbaI, blunting the ends with the Klenow fragment of DNA pol I,
and ligating the ends, resulting in pVA-ls6-B. Then, the HindIII-to-AflIII frag-
ment (274 bp) containing the tat sequence from pCMV-Tat was ligated between
the BamHI and BglII sites of pVA-ls6-B. Before ligation, all sites were blunted
by filling in the 39 recess with the Klenow fragment of DNA pol I. Mutations were
made by the site-directed mutagenesis procedure of Zoller and Smith (73).
Mutations at sites A and B are described below. Mutations at sites I and S
changed the translation start codon, AUG (nucleotides [nt]144 to146), and the
termination codon, TAG (between nt 186 and 188), of the upstream ORF to
GCG and CAG, respectively. Mutant I1S is a double mutant with both the
initiator and termination codons mutated. Runs of thymidines were created at
1100 (mutant T1), upstream of the Tat-coding region, and at1234 (mutant T2),
in the coding region, without altering the amino acid sequence of the protein. All
mutant constructs were sequenced to confirm the mutation sites. pGEM-Tat120
was constructed by inserting the HindIII-to-MunI fragment from pCMV-Tat,
containing the 59 end of the tat sequence, between the HindIII and EcoRI sites
of pGEM-1 (Promega). Plasmid pT7 VA-Tat was transcribed in the presence or
absence of m7GpppG to synthesize capped and uncapped VA-Tat RNA in vitro
(22a).
Other plasmids. pHIV-CAT is a deletion construct of pU3RIII (p-167 [58])
that contains the CAT reporter gene driven by 2167 to 182 of the HIV-1 long
terminal repeat (LTR). pDS-CAT contains a 4-nt deletion from 135 to 138 in
the TAR region of pHIV-CAT which makes it nonresponsive to Tat transacti-
vation. pCMV-Tat is the same as pBC/CMV/t2 (10) and contains the immediate-
early gene promoter of human cytomegalovirus (CMV) upstream of the SalI-to-
KpnI fragment of the tat gene, encompassing the first coding exon and 304 bp of
the adjacent intron sequence. paa1c contains the human a-globin gene under
the control of its own promoter (69). pb-Gal expresses b-galactosidase (b-Gal)
under the control of the CMV immediate-early promoter (pON260 [67]).
HIV LTR transactivation assay. HeLa cells grown to 50% confluency in
6-cm-diameter plates were transfected by the calcium phosphate method (25).
pUC119 was added as a carrier to a total of 15 mg per plate. All plates were
transfected with 1 mg of pb-Gal. The cells were harvested at 48 h posttransfec-
tion, and lysate prepared by freezing and thawing was assayed for CAT enzyme
activity by standard procedures (25). The b-Gal assay was performed as de-
scribed by Herbomel et al. (23). b-Gal activity was expressed as the optical
density at 420 nm obtained with 25 ml of the lysate incubated at 378C for 1 h;
b-Gal activity was used to normalize the CAT enzyme activity for transfection
efficiency. The relative CAT activity is defined as the percentage of chloram-
phenicol acetylated by 1 ml of the cell lysate at 378C in 1 h, corrected for b-Gal
activity.
RNA analysis. Cytoplasmic RNA was prepared following lysis with Nonidet
P-40 as described by Anderson et al. (1). Total cytoplasmic RNA was used for
Northern (RNA) blot analysis with an RNA probe complementary to the 59 end
of the VA RNA sequence (26). RNase protection analysis was conducted as
described by Laspia et al. (37). An RNA probe complementary to the tat se-
quence was synthesized with T7 RNA polymerase from pGEM-Tat120 linearized
with NheI. An RNA probe complementary to the a-globin sequence was made
with SP6 polymerase from paa1c linearized with BamHI by using [a-32P]UTP
from ICN Radiochemicals, Inc. Oligo(dT) cellulose column chromatography of
RNA was performed by a standard protocol (41). RNA was 39 end labeled with
[59-32P]pCp and T4 RNA ligase as described by England and Uhlenbeck (13) and
59 end labeled with [a-32P]ATP and polynucleotide kinase as described by Mellits
and Mathews (45).
Polysome isolation. Cells from 10-cm-diameter plates were harvested at 48 h
posttransfection and suspended in 0.2 ml of TSM buffer (10 mM Tris-Cl [pH 7.6],
150 mMNaCl, 2 mMMgCl2) containing 0.5% Nonidet P-40. After 15 min on ice,
cell debris was removed by centrifugation, and 100 ml of the supernatant was
layered on 3.5 ml of 15% sucrose in TSM. The concentration of NaCl was
adjusted to 0.5 M in the remaining 100 ml of the lysate, which was then layered
onto 15% sucrose in TSM containing 0.5 M NaCl. After centrifugation in a
Beckman TLA 100.3 rotor at 75,000 rpm for 45 min, pellets were suspended in
TSM And RNA was isolated for analysis. To examine polysome profiles, cell
lysates were prepared as described above, layered on an 11-ml 15 to 35% sucrose
gradient, and centrifuged at 35,000 rpm for 2 h in a Beckman SW 60.1 rotor. The
gradients were pumped through an ISCO UV monitor, and 1-ml fractions were
collected for RNA extraction.
Capping reaction. RNA was 59 end labeled with vaccinia virus guanylyltrans-
ferase (47). Reactions were performed in a final volume of 50 ml containing 25
mM Tris-Cl (pH 7.8), 2 mM MgCl2, 1 mM dithiothreitol, 60 mM NaCl, 6 mM
KCl, 80 U of RNasin, 0.1 mM S-adenosylmethionine, 5 mM GTP, 0.1 mCi of
[a-32P]GTP, 5 mg of RNA, and 4 U of guanylyltransferase (Gibco). The reaction
mixture was incubated at 378C for 30 min, after which 10 mM EDTA and 0.4%
sodium dodecyl sulfate were added to terminate the reaction. The RNA was
extracted with phenol and chloroform, ethanol precipitated, and then subjected
to hybrid selection for the VARNA sequences with pVA or for tat sequences with
pCMV-Tat as described by Ausubel et al. (2).
Immunoprecipitation. Polyclonal antibody directed against m7G cap (kindly
provided by Ted Munns and E. Lund) was bound to protein A-Sepharose CL-4B
beads and used for immunoprecipitating RNA as described by Terns et al. (70).
RNase H analysis of RNA. Reaction mixtures containing 5 mg of end-labeled
RNA were incubated with RNase H in the presence or absence of 0.3 mg of
poly(dT) as described by Mercer and Wake (46). The products of the reactions
were analyzed by electrophoresis in an 8% polyacrylamide–7 M urea gel, either
directly or after hybrid selection with pVA-Tat.
RESULTS
Expression of pVA-Tat. Cellular mRNA and primary tran-
scripts made by pol II appear to follow a defined pathway
through the nucleus and into the cytoplasm as they are pro-
cessed, transported, and utilized for translation (for a review,
see reference 68). Although abundant and stable cytoplasmi-
cally located transcripts are produced by pol III, none of these
is known to encode a protein. To determine whether transcrip-
tion by pol III is compatible with recruitment of the RNA
product for translation, we constructed a vector, pVA-Tat, in
which the HIV-1 Tat-coding sequence is driven by the adeno-
virus VA RNA promoter, a strong pol III promoter. Its chief
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elements are intragenic in that two essential regions of the VA
RNA promoter known as the A and B boxes are present
downstream of the transcriptional start site (15, 21; for a re-
view, see reference 19). Therefore, the promoter sequence is
transcribed as the 59 end of the RNA. This promoter has been
used previously by us and others to generate short RNAs in
vivo (22, 38). Inserted between the internal promoter region of
VA RNA and its termination signal, which lies in a run of four
thymidine residues (Fig. 1A), is the first coding exon sequence
of the HIV-1 Tat protein. The substitution removes VA RNA
sequences that are essential for its role in translational control
(43).
Transcription by pol III was expected to give rise to an RNA
of 368 nt, consisting of 75 nt from the VA RNA promoter
followed by 277 nt of the tat sequence and 16 nt of the VA
RNA sequence and ending in the 39 run of four uridines. Both
in a pol III transcription system (Fig. 1B) and in transfected
cells (Fig. 1C), pVA-Tat produced the predicted RNA. The
parent plasmid pVA, encoding VA RNAI, and a control plas-
mid (pVA-antiTat, containing a portion of the tat gene in-
serted in the opposite orientation) also produced the tran-
scripts expected (Fig. 1).
To examine the translational potential of the VA-Tat tran-
script, we assayed its ability to produce Tat protein in trans-
fected cells, taking advantage of Tat’s capacity to transactivate
expression from the HIV promoter containing the TAR re-
gion. HeLa cells were transfected with the reporter plasmid
pHIV-CAT, and CAT enzyme activity in cell lysates was sub-
sequently measured. Cotransfection with pVA-Tat caused a
large increase in CAT activity (Fig. 2A), whereas plasmids that
do not encode Tat-coding sequence (pVA and pVA-antiTat)
elicited no effect (Fig. 2A). Comparable amounts of RNA
accumulated in cells transfected with all three plasmids, as
determined by Northern blot analysis (Fig. 1C). The response
to pVA-Tat was concentration dependent (Fig. 2B), but it
saturated at considerably lower levels than did the response to
pCMV-Tat, which contains the Tat-coding sequence under the
control of the immediate-early CMV promoter (Fig. 2A).
Transactivation of the HIV LTR by Tat is dependent on the
protein’s interaction with TAR RNA and is accordingly sensi-
tive to mutations in the TAR region (for a review, see refer-
ence 51). To verify the specificity of transactivation by pVA-
Tat, a mutant reporter construct, pDS-CAT, containing a 4-nt
deletion within the TAR region, was cotransfected with pVA-
Tat or with pCMV-Tat. No CAT activity was observed (Fig.
2A), confirming that transactivation by pVA-Tat is due to the
production of Tat protein.
VA-Tat expression is dependent on pol III transcription.
The data in Fig. 2 demonstrate the synthesis of functional Tat
protein from pVA-Tat and lead to the presumption that Tat
can be made from a pol III transcript. However, they do not
exclude the possibility of a cryptic pol II promoter directing the
synthesis of VA-Tat RNA. Both in vivo and in vitro, synthesis
of VA-Tat RNA exhibited the sensitivity to the drug a-aman-
itin that would be expected of a pol III transcript (data not
shown). For a more definitive test, we examined the effects of
mutations that are deleterious to pol III transcription and
would not be expected to affect transcription by pol II. Three
mutations targeted the two essential elements of pol III tran-
scription within the VA RNA gene promoter, the A and B
boxes, situated between nt 14 and 24 and nt 59 and 69, respec-
tively (Fig. 3A). Mutational analysis of these two regions of the
VA RNA promoter has shown that substitutions of G16 (the
guanosine nucleotide at 116) and G60 are very deleterious to
transcription (56). Accordingly, U14 and G16 were mutated to
adenosine residues by oligonucleotide-directed mutagenesis to
FIG. 1. pol III transcripts. (A) Schematic diagram of the plasmids. (B) Expression of the plasmids in vitro with a pol III transcription system (44). The RNA products
were analyzed in an 8% polyacrylamide–7 M urea gel. End-labeled DNA markers (pBR332 cut with HpaII) are shown on the right (lane M; sizes in nucleotides). (C)
Expression of the plasmids in vivo. RNA from cells transfected with the respective plasmids was analyzed by Northern blot analysis with the 59 VA probe.
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create the site A mutant, and G59 and G60 were changed to
adenosine residues to create the site B mutant (Fig. 3A). A
double mutant (A1B) was also constructed where both ele-
ments were mutated simultaneously. As expected, these muta-
tions greatly decreased transcription in vitro in a pol III tran-
scription system (Fig. 3B, lanes 3 and 5). Combining the A and
B box mutations essentially abolished transcription (lane 6).
Two further mutants were made by creating pol III termi-
nation signals within the VA-Tat sequence. Without altering
the amino acid-coding sequence of the gene, a run of five
thymidine residues was placed before the protein-coding se-
quence (site T1 [Fig. 3A]) and a second T-rich stretch (TTT-
TATT) was inserted within the Tat-coding region (site T2 [Fig.
3A]). Both of these mutations were expected to produce trun-
cated RNA; the T1 mutant RNA should lack the entire pro-
tein-coding sequence, while the T2 mutant RNA should en-
code a protein lacking the C-terminal 33 amino acids of the Tat
protein. The C-terminal sequence of Tat includes the basic
domain, which is essential for its nuclear localization and in-
teraction with TAR RNA, so this mutation should eliminate
the transactivation function. In the pol III transcription system,
the termination signal at site T2 caused truncation of most of
the RNA produced (Fig. 3B, lane 7). Surprisingly, the muta-
tion at site T1 had no effect (Fig. 3B, lane 6). The reason for
this is not clear, because the mutation creates a run of five T
residues situated in a GC-rich context which, according to
earlier work (5), should make a strong signal for pol III ter-
mination.
The ability of these VA-Tat mutants to generate functional
Tat was tested in the transactivation assay. Figure 3C shows
that the promoter mutations A and B separately reduced CAT
enzyme accumulation; together in one mutant (mutant A1B),
they almost eliminated transactivation. The effective termina-
tion signal, T2, severely reduced CAT activity, while the inef-
fective signal, T1, was nearly as active as the wild-type pVA-
Tat in the CAT transactivation assay. Examination of RNA
from the transfected cells by Northern blot analysis (Fig. 3D)
confirmed that T2 RNA was stable, although truncated,
whereas T1 RNA was similar to wild-type VA-Tat RNA in size
and amount, as expected from Fig. 3B. When installed in a pol
II transcription unit, neither mutation T1 nor T2 had any effect
on transactivation by Tat, as expected (data not shown). Little
RNA was detected from mutants A and B, and even less was
detected from the double mutant, A 1 B. These results are
consistent with the in vitro transcription data (Fig. 3B) and
with the Tat transactivation activities of the mutants (Fig. 3C),
with one exception. Although transactivation was reduced by
FIG. 2. Functionally active Tat protein is produced in pVA-Tat-transfected
cells. (A) HIV LTR transactivation assay. HeLa cells were transfected with
pHIV-CAT or the deletion mutant plasmid pDS-CAT alone or with specified
amounts of pVA, pVA-antiTat, pVA-Tat, or pCMV-Tat. The cell lysates were
assayed for CAT enzyme activity. The actual CAT enzyme activity is indicated as
the percentage of chloramphenicol acetylated by 25 ml of the cell extract in 1 h.
(B) Dose-response curve of pVA-Tat, pVA, and pVA-antiTat transactivation
activities. The relative CAT enzyme activity is shown as CAT units per microliter
of the lysate, corrected for b-Gal activity (an indicator of transfection efficiency).
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the A mutation by only about 40% (Fig. 3C), very little RNA
was evident in the transfected cells, which is suggestive of an
RNA detection problem. As expected, the A mutation reduced
expression in the A1B mutant, relative to expression from the
B mutant. This anomaly notwithstanding, the data from the
mutants indicate that pol III transcription is essential for the
production of VA-Tat RNA and for transactivation of HIV
CAT. Therefore, the VA-Tat RNA that is translated is indeed
a pol III product and not derived from a cryptic pol II pro-
moter.
VA-Tat RNA is not capped or polyadenylated. Unlike pol II
transcripts, most pol III RNAs are neither polyadenylated at
the 39 end nor capped at the 59 end, so we would expect
VA-Tat transcripts to lack these posttranscriptional modifica-
tions. To investigate the polyadenylation status of VA-Tat
RNA, RNA from pVA-Tat-transfected cells was subjected to
oligo(dT) cellulose column chromatography. The column frac-
tions were examined by Northern blot analysis (Fig. 4A, top).
VA-Tat RNA did not bind to the column and was recovered
with poly(A)2 species in the flowthrough and wash fractions
(Fig. 4A, lanes 3 to 5). As a control, the cells were cotrans-
fected with plasmid aa1c, which expresses the a-globin gene
under the direction of pol II. The a-globin mRNA bound to
the oligo(dT) cellulose column (Fig. 4A, bottom) and was
FIG. 3. Effect of mutations in RNA pol III transcription signals on transac-
tivation by pVA-Tat. (A) Sites of the mutations in pVA-Tat. (B) Products of in
vitro transcription by pol III of pVA (lane 1), wild-type pVA-Tat (lane 2), and
mutant pVA-Tat constructs (lanes 3 to 7) analyzed in an 8% polyacrylamide–7 M
urea gel. Lane 8 contains products of a control reaction carried out in the
absence of template DNA. End-labeled DNA markers are shown on the right
(lane M). (C) HIV CAT transactivation by wild-type (wt) and mutant pVA-Tat.
The relative CAT enzyme activity is shown as CAT units per microliter of the
lysate, corrected for b-Gal activity (an indicator of transfection efficiency). The
bar labeled with the minus sign indicates basal activity from pHIV-CAT alone.
(D) Total cytoplasmic RNA from cells transfected with wild-type (lane 2) or
mutant (lanes 2 to 8) pVA-Tat was subjected to Northern blot analysis with the
59 VA probe. The position of wild-type VA-Tat RNA is indicated on the left, and
RNA markers are shown on the right.
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eluted with 0.5 M salt as expected for a polyadenylated RNA.
Because this assay might not detect RNAs with poly(A) tails of
less than 20 nt (46), we conducted a more sensitive test with
RNase H, an enzyme that degrades the RNA strands of an
RNA:DNA heteroduplex. The RNA from pVA-Tat-trans-
fected cells was labeled at its 59 end with polynucleotide kinase
and [g-32P]ATP or at its 39 end with RNA ligase and [32P]pCp.
VA-Tat RNA was isolated by hybrid selection and incubated
with RNase H in the presence or absence of poly(dT). Under
these conditions, synthetic poly(A) was completely digested
provided poly(dT) was present (data not shown). Regardless of
the site of the end label, VA-Tat RNA was unaffected by
RNase H whether poly(dT) was present or not (Fig. 4B, lanes
2 to 5), which is consistent with its poly(A)2 status. Poly(A)
tails as short as 5 nt have been detected in this way (11),
thereby placing an upper limit of five on the number of A
residues that might be present at the 39 end of VA-Tat RNA.
We also used a label transfer protocol to determine the 39-
terminal nucleotide of VA-Tat RNA. After being labeled with
[32P]pCp at its 39 end, VA-Tat RNA was digested with alkali,
and the resultant 39 nucleoside monophosphates were sepa-
rated by paper electrophoresis (data not shown). Most of the
label (about 70%) was in UMP, as expected if the VA-Tat
RNA terminated at the VA RNA termination site. Some label
(about 25%) was also detected in AMP, raising the possibility
that a fraction of the molecules end in adenosine or carry a
short oligo(A) tract. Such tracts, if they existed, would be
released by digestion of end-labeled VA-Tat RNA with a mix-
ture of RNases T1 and A, which cleave after U, C, and G
residues. Upon gel electrophoresis, the vast majority of the
label migrated as a trinucleotide or faster (mostly as a mono-
nucleotide), suggesting that the A label is likely due to the
addition of pCp to internal positions of broken VA-Tat RNA
molecules. We therefore conclude that little or none of the
VA-Tat RNA carries a poly(A) tail.
Primer extension analysis precisely mapped the 59 end of
VA-Tat RNA to the start site of VA RNA (data not shown),
and the fact that VA-Tat RNA can be 59 end labeled by
polynucleotide kinase (Fig. 4B, lanes 2 and 3) implies that
some or all of it has a free 59 end, at least after phosphatase
treatment. These data suggested that the 59 end of VA-Tat
RNA is probably uncapped and that it might be a substrate for
the capping reaction. Guanylyltransferase, better known as
capping enzyme, transfers a guanylyl nucleotide onto the 59
end of an RNA provided the RNA is not already capped and
carries a 59 di- or triphosphate nucleotide, therefore excluding
59 ends created by degradation (47). Consequently, guanylyl-
transferase, in the presence of [a-32P]GTP, should label VA-
Tat RNA if it is produced by pol III. RNA from transfected
cells was subjected to the capping reaction in the presence of
labeled GTP, followed by hybrid selection for VA RNA or tat
RNA sequences and analysis by gel electrophoresis. The VA-
Tat RNA gave a band of the expected size (Fig. 5A, lanes 2 and
7), indicating that it is uncapped in vivo. As a positive control,
a known pol III product, VA RNA from cells transfected with
pVA, was also labeled in the capping reaction (Fig. 5A, lane 3).
On the other hand, RNA from cells transfected with pCMV-
Tat remained unlabeled, as expected for a pol II transcript
which is already capped in vivo. To confirm this result, we used
antibodies directed against the 59 cap structure to examine
VA-Tat RNA for the presence of caps. The antibody precipi-
tated capped VA-Tat RNA, synthesized in vitro by T7 RNA
polymerase in the presence of m7GpppG (Fig. 5B, lanes 4 to
6), but not uncapped VA-Tat RNA, synthesized in the absence
of the methylated nucleotide (Fig. 5B, lanes 1 to 3). When
cytoplasmic RNA isolated from transfected cells was analyzed
with the antibody, no VA-Tat RNA was detected in the im-
munoprecipitate, suggesting that little or none of it was capped
(Fig. 5B, lanes 7 to 9). Thus, the VA-Tat RNA produced in
transfected cells is not detectably polyadenylated or capped,
which is consistent with transcription by pol III.
Polysomal association of VA-Tat RNA. The demonstration
that VA-Tat RNA can be capped shows that some, though not
necessarily all, of this RNA lacks a cap structure. Capped RNA
is translated better than uncapped RNA in vitro (62) and in
vivo (17, 57), so it was conceivable that an undetected, small
fraction of the VA-Tat RNA is capped and that this RNA is
translated whereas the uncapped VA-Tat RNA is not recruited
by the ribosomes for translation. To test this hypothesis, we
analyzed the RNA that is associated with polysomes from
FIG. 4. VA-Tat RNA is not polyadenylated. (A) RNA from cells transfected with pVA-Tat and paa1c was fractionated in an oligo(dT) cellulose column. The
starting material (lane 2), first flowthrough fraction (lane 3), 0.1 M NaCl wash fractions (lanes 4 and 5), and eluate (lane 6) were subjected to Northern blot analysis
with the 59 VA probe (top panel). The bottom panel shows RNase protection analysis with a probe complementary to a-globin. RNA from mock-transfected cells was
run in lane 1. Lanes 1 to 5 contain equivalent portions of RNA; lane 6 contains three times this amount. RNA marker sizes are given on the right. (B) RNA from cells
transfected with pVA-Tat (lanes 2 to 5) or mock-transfected cells (lane 1) was 39 or 59 end labeled, selected by hybridization with pVA-Tat DNA, and then subjected
to RNase H digestion in the presence or absence of poly(dT), as indicated. Reaction products were analyzed in an 8% polyacrylamide–7 M urea gel. End-labeled DNA
markers in nucleotides are given on the right.
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transfected cells. RNAs that are actively translated are tightly
bound to polysomes and cannot be dislodged by high-salt treat-
ment, unlike many of the accessory components of the trans-
lational apparatus (including the protein kinase DAI and VA
RNA, which associates with it). Therefore, if uncapped VA-
Tat RNA is translated in the transfected cells, it should be
associated with the polysomal fraction of the cell in a salt-
stable manner.
Polysomal pellets were prepared from transfected cell ly-
sates under low-salt or high-salt conditions, and the RNA
extracted from the pellets was examined by Northern blot
analysis with a probe complementary to the 59 end of VA
RNA. VA-Tat RNA was present in the polysomal pellet pre-
pared under both low-salt and high-salt conditions (Fig. 6A,
lanes 5 and 11). VA RNA, in contrast, was found in the poly-
somal pellet prepared under the low-salt conditions but not
under the high-salt conditions (Fig. 6A; compare lanes 6 and
12). Like VA-Tat RNA, CMV-Tat RNA was also associated
with the polysomal pellet in a salt-stable manner, as would be
expected of an mRNA (data not shown). To determine
whether the VA-Tat RNA that is stably associated with the
polysomal pellet was also uncapped, we subjected it to the
guanylyltransferase reaction followed by hybrid selection for
VA RNA sequences as described above. The ribosome-asso-
ciated RNA was labeled in the capping reaction (Fig. 6B, lane
4), demonstrating that uncapped VA-Tat RNA is recruited for
translation by the ribosomes.
Similar results were obtained when polysomes were exam-
ined by sucrose gradient sedimentation in the presence of a
high concentration of salt. Figure 6C displays the distribution
of tatRNA from cells transfected with pVA-Tat or pCMV-Tat.
VA-Tat RNA was found preferentially in the monosome peak
with small amounts in the disome peak and traces in the poly-
some region of the gradient. CMV-Tat, by contrast, was
present in the monosome peak, with larger amounts in the
disome peak and substantial amounts in the polysome region.
Thus, both species are loaded onto ribosomes but CMV-Tat
RNA is more efficiently incorporated into large polysomes
than is VA-Tat RNA. A shift to smaller polysomes often ac-
companies a decrease in the rate of initiation on an mRNA
species. Given the small size of tatmRNA, it is difficult to draw
firm conclusions in this case, but the differential loading sug-
gests that initiation may be the rate-limiting step for VA-Tat
RNA translation.
Finally, in case there exists a small fraction of the VA-Tat
RNA which is capped and preferentially associated with trans-
lating ribosomes, we examined fractions from the gradient by
immunoprecipitation with anticap antibody (Fig. 6D). Again,
no capped VA-Tat RNA was detected in any fraction, con-
firming our previous conclusion on this point.
Do ribosomes scan VA-Tat RNA? It appears from the data of
Fig. 2B that Tat production from pVA-Tat was about 100-fold
less efficient than Tat production from pCMV-Tat, and Fig. 6C
shows that VA-Tat RNA is less efficiently loaded onto poly-
somes than is CMV-Tat RNA. Several factors may contribute
to the low translational efficiency. One of these is the existence
of an AUG initiator codon in the VA RNA sequences up-
stream of the Tat-coding region. The 59 untranslated region of
VA-Tat RNA is 123 nt long and contains an ORF between nt
44 and 88 that is out of frame with that of Tat. Such upstream
ORFs can reduce the translation of a downstream ORF, es-
pecially if the ORF begins with an AUG in a favorable context,
an observation that is commonly interpreted to imply that
initiating ribosomal subunits first bind to the 59 cap and then
scan along the mRNA until they encounter a suitable AUG
(32). To discover whether the upstream ORF plays any role in
the translation of VA-Tat RNA, we eliminated it by mutating
the start codon to GCG (mutant I) or extended it by 10 nt into
the Tat ORF by mutating the upstream stop codon to CAG
(mutant S) (Fig. 6A). The initiation codon mutant gave only
twofold more CAT activity than wild-type pVA-Tat and the
stop codon mutant gave twofold less activity than wild-type
pVA-Tat in the HIV LTR transactivation assay (Fig. 6B),
suggesting that the upstream ORF can be translated and that
its utilization decreases Tat synthesis. Consistent with this con-
clusion, transactivation by the double mutant I1S was similar
to that of the I mutant, indicating that the stop codon is
influential only if the upstream ORF is utilized. These results
indicate that scanning of the 59 untranslated region may be
involved in translation of the uncapped VA-Tat RNA.
DISCUSSION
It is an accepted fact that pol II produces mRNA precursors
in eukaryotic cells. We have asked whether this marked func-
tional specialization is obligatory or facultative; in other words,
is the synthesis of mRNA necessarily and exclusively a pol II
function? To address this question, we determined whether pol
III can make functional mRNA by examining the transcrip-
tional ability and translational potential of a chimera contain-
ing a protein-coding sequence under the control of a pol III
FIG. 5. VA-Tat RNA is uncapped. (A) The RNA from cells transfected with
pVA-Tat (VT; lanes 2 and 7), pVA (VA; lane 3), or pCMV-Tat (CMV; lane 8)
or from mock-transfected cells (M; lanes 1 and 6) was subjected to the capping
reaction in the presence of [a-32P]GTP followed by hybrid selection for the VA
RNA sequence (lanes 1 to 3) or the tat sequence (lanes 6 to 8). The selected
RNA was analyzed in an 8% polyacrylamide–7 M urea gel. Lanes 1 to 5 contain
equivalent portions of the RNA; lane 6 contains three times this amount. End-
labeled DNA markers (lanes 4 and 5) are given between the panels (in nucle-
otides). (B) Uncapped (lanes 1 to 3) or capped (lanes 4 to 6) VA-Tat RNA
transcribed in vitro or RNA from pVA-Tat-transfected cells (lanes 7 to 9) was
immunoprecipitated with a cap-specific antibody and analyzed in an 8% poly-
acrylamide–7 M urea gel or by Northern blot analysis, respectively. Lanes
marked ‘‘S’’ contain the starting material; lanes marked ‘‘C’’ and ‘‘I’’ contain
material immunoprecipitated in the absence or presence of the anticap antibody,
respectively.
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promoter. Our results demonstrate that RNA transcribed by
pol III can indeed serve as mRNA and give rise to a functional
protein in the absence of a 59 cap, a 39 poly(A) tail, and intron
removal, which have been proposed to be indispensable fea-
tures of eukaryotic mRNA. A combination of biochemical and
mutational evidence established that the transcript is a genuine
product of pol III transcription rather than a product of tran-
scription from a cryptic pol II promoter. Mutants targeting the
VA RNA gene promoter elements or inserting termination
signals specific for pol III had the expected effects on Tat
synthesis, while biochemical analysis demonstrated that the
VA-Tat RNA was nonpolyadenylated and uncapped, as ex-
FIG. 6. Polysome association of VA-Tat RNA. (A) The lysate from cells transfected with pVA-Tat (VT) or pVA (VA) or from mock-transfected cells (M) was
fractionated into ribosomal and cytosolic components under low- or high-salt conditions. RNA from the total lysate or the ribosomal fraction was subjected to Northern
blot analysis with the 59 VA probe. The positions of VA RNA and VA-Tat RNA are marked. (B) RNA from the total lysate or the ribosomal pellet was labeled in
the capping reaction, hybrid selected for VA sequences, and analyzed in an 8% polyacrylamide–7 M urea gel. VT, VA-Tat RNA; M, mock-transfected cells. End-labeled
DNA markers (in nucleotides) are given on the right. (C) Sucrose gradient analysis of polysomes from transfected cells. The lysate prepared from cells transfected with
pVA-Tat or pCMV-Tat was fractionated in a sucrose gradient under high-salt conditions. RNA extracted from the fractions collected was subjected to RNase protection
analysis with a probe complementary to the tat sequence. The protected product was quantified with a Fuji Phospho Imager. The positions of the supernatant (sup),
40S subunit, monosomes (mono-), disomes (di-), and larger polysomes are indicated. (D) Polysome-associated VA-Tat RNA is not capped. Lysates of cells transfected
with pVA-Tat (VT) were resolved in sucrose gradients run under high-salt or low-salt conditions. The fractions containing the supernatant (Sup), monosomes (Mono),
and polysomes (Poly) were pooled. RNA extracted from these fractions was subjected to immunoprecipitation with the cap antibodies (lanes I) and analyzed by
Northern blot analysis with the 59 VA probe. Lanes marked ‘‘S’’ contain the starting material.
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pected of a pol III transcript. Moreover, polysome-associated
VA-Tat RNA was uncapped, confirming that the pol III tran-
script was indeed translated. The results obtained in this model
system have implications for mRNA synthesis and utilization,
as well as for RNA polymerase selectivity.
mRNA production. Despite the structural and functional
distinctions between the three types of cellular RNA poly-
merase, some common features have come to light in recent
years. For example, the TATA-element-binding protein is es-
sential for the function of all three polymerases (for a review,
see reference 24), and one class of pol III promoters is so
similar in primary structure to a pol II promoter that its spec-
ificity can be switched by the elimination of a functional TATA
element (39). At the level of processing, although some studies
have shown that splicing of RNA is coupled to pol II transcrip-
tion (64), other studies have shown that these two processes
can be dissociated (20, 34). Moreover, polyadenylation, which
was thought to be undertaken only by pol II transcripts, has
been reported for naturally occurring pol III transcripts in
murine tumor cells (35, 36, 63) as well as for a chimeric RNA
transcribed by pol III (38). A low-abundancy b-globin tran-
script that initiates upstream of the normal b-globin mRNA
initiation site and is transcribed by pol III has been reported to
be present in bone marrow cells and in peripheral blood re-
ticulocytes (8). These pol III transcripts are polyadenylated
and spliced correctly, like the normal b-globin mRNA. Taken
together, these observations provide some precedents, albeit
fragmentary, for the synthesis of mRNA by pol III reported
here. Furthermore, Alu elements, which are transcribed by pol
III, are found within protein-coding sequences (7, 42, 61, 72).
Nevertheless, as far as we are aware, no cellular mRNA has
been shown to be produced by a polymerase other than pol II.
On the other hand, many viruses make mRNA by using viral
RNA polymerases, circumventing the highly specialized path-
ways for mRNA processing, transport, and utilization em-
ployed by cellular genes. Some viruses, such as vaccinia virus,
reovirus, and poliovirus, have resorted to transcription in the
cytoplasm of the host cell to bypass the processing and trans-
portation complication. The transcripts of these viruses are
capped by virus-specific enzymes and translated like cellular
pol II transcripts. Other viral genomes, like that of influenza
virus, are transcribed in the nucleus and the transcripts are
correctly transported and translated, implying that the speci-
ficity of the pathways is not rigorously maintained or that viral
mRNAs gain access to the normal pathway at intermediate
points. Evidently, pol III transcripts can enter these pathways
or utilize alternative routes leading from the nucleus to the
polysome. From the results shown in Fig. 2, however, it could
appear that expression of Tat from pVA-Tat saturates at a
relatively low level, despite the accumulation of the pol III
transcript to high levels. Thus, there seems to be a bottle-
neck(s) at one or more steps in the pathway.
Translational initiation. All known cellular mRNAs are
capped, and most of them are spliced and polyadenylated.
According to the scanning hypothesis, the cap plays an impor-
tant role in translational initiation: the 40S ribosomal subunit
is thought to bind at the 59 end of the RNA, an event which is
facilitated by the cap and a cap-binding initiation factor (eIF-
4E), and then to migrate along the RNA until it encounters the
first AUG codon, at which it initiates translation (for a review,
see reference 32). Three kinds of exceptions to this model are
recognized: the first AUG can be bypassed if it is in a subop-
timal sequence context or duplex structure, its utilization can
be influenced by initiation factors and conditioned by prior
short ORFs (18; for a review, see reference 33), and it can be
disregarded if the RNA contains an IRES (for a review, see
reference 66). IRES elements are found in uncapped picorna-
virus RNAs and even in the naturally capped mRNAs of hep-
atitis C virus and some cellular mRNAs which have a longer-
than-average 59 untranslated region. The IRES confers cap-
independent translation upon the mRNA, playing a role
analogous to that of the cap structure in binding the 40S
ribosomal subunit to the mRNA for translation but permitting
initiation at a downstream AUG codon. A more recent scan-
ning model (66) proposes that initiation factor complexes,
rather than ribosomal subunits, scan the 59 region and ad-
vances the idea that scanning may not be 59 end dependent.
Scanning by the initiation factors is proposed to cause unwind-
ing of the RNA, thereby creating a site for ribosome binding
and leading to initiation. Whatever the mechanism, our data
show that the presence of a cap is not essential.
Under some circumstances at least, the poly(A) tail found at
the 39 end of most eukaryotic mRNAs is required for mRNA
stability, its transport into the cytoplasm, and its efficient trans-
lation (for a review, see reference 29). In particular, a poly(A)
tail has been implicated in the initiation of translation (48).
The poly(A)-binding protein, which is present in almost all
eukaryotic cells and which forms a complex with the poly(A)
tail, also enhances initiation (59), supporting the view that the
poly(A) tail plays a role in translation. On the other hand,
there are observations that argue against the universality of the
stimulatory role of poly(A) in translation. For example, a de-
ficiency of poly(A)-binding protein or lack of poly(A) tails did
not significantly affect the translational efficiency of yeast
mRNAs (53); deadenylated zein mRNA is translated 50% as
efficiently as poly(A)1 mRNA in microinjected Xenopus oo-
cytes (16), and deadenylation of histone mRNA actually facil-
itates translation of histone messages in Xenopus oocytes (3).
Our results show that the translation of the pol III transcript
can occur in the absence of a poly(A) tail, but further studies
are needed to determine if polyadenylation of the pol III
transcript can improve its translational efficiency.
VA-Tat RNA contains a short 59 ORF of 45 nt upstream of
the Tat ORF, with 37 nt intervening between them. A mutation
in the upstream AUG, which in effect abolished the short
ORF, resulted in a modest increase in Tat transactivation, and
mutation of the stop codon of the upstream ORF gave only a
twofold decrease in transactivation (Fig. 7). Although these
effects are in principle compatible with scanning, their magni-
tude was small. At least three explanations can be entertained.
First, it is possible that the first AUG is ‘‘leaky’’ (allowing
bypass), even though it is in a good context for initiation
(AUCAUGG), perhaps because the fidelity of the scanning
mechanism is lower if a cap is absent. Leaky initiation codons
that are present in a favorable context, although uncommon,
have been reported earlier (12, 49). Second, under certain
circumstances ribosomes can reinitiate at a downstream AUG
after terminating at an upstream stop codon (27, 31). However,
the intercistronic sequence of VA-Tat RNA may be too short
for efficient reinitiation (31). Mutation at site S extends the
upstream ORF so that it overlaps the Tat ORF by 10 nt. In
light of the finding by Peabody et al. (50) that ribosomes can
scan backward for up to 50 nt and reinitiate at the AUG of the
downstream ORF, it is conceivable that reinitiation at the
downstream AUG occurs by back scanning after translation of
the upstream ORF terminates. Increasing the overlap of the
two ORFs reduced translation of the downstream tat ORF,
indicating back scanning as a strong possibility in mutant S
(unpublished data). Third, perhaps ribosomes bind to un-
capped mRNA in a random fashion and migrate to the nearest
AUG, where they initiate translation. Those ribosomes that
bind between the two AUGs would not be affected by muta-
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tions that eliminate the upstream ORF (mutants I and I1S) or
by those that extend the ORF into the Tat ORF (mutant S),
thereby accounting for the relatively small effect of these mu-
tations. Although the existence of an IRES in the 59 untrans-
lated region of the RNA has not yet been ruled out, the small
size and lack of secondary structure in the 59 untranslated
region make it unlikely.
Polymerase selectivity. The demonstration that mRNA can
be produced by pol III raises two related questions: are any
cellular mRNAs made by pol I or pol III, and how and why do
cells preserve pol II as the predominant, if not exclusive,
source of mRNA? The maintenance of specificity may confer
advantages, such as correct processing and transportation, that
allow an efficient utilization of the transcript and may even
provide specific signals for regulation of gene expression. Be-
cause an artificial pol III transcript can also be translated, cells
may also impose functional limitations that maintain the dis-
tinct specialization of the polymerases. One of the obvious
limitations in the case of pol III is the requirement that the
RNA be free of runs of T residues, but the degeneracy of the
genetic code is such that this obstacle should not be insuper-
able. Moreover, our data indicate that the termination signal
may be more complex than previously suspected, since, for
reasons not understood, pol III ignored a stop signal (mutant
T1) even though it was surrounded by GC-rich sequences.
Some yeast viral mRNAs are uncapped (6), and their transla-
tion is suppressed by the yeast chromosomal gene SKI2, which
is proposed to be a part of a cellular defense mechanism (71).
SKI2 blocks the translation of uncapped messages only, and
disruption of the SKI2 gene led to increased translation of a
pol I-directed mRNA which supposedly is uncapped. Such
cellular defense mechanisms against viral infection may also
impose limitations that maintain the specificity of the poly-
merases.
It is also possible that the promoter sequence dictates poly-
merase selection, which in turn leads the transcript through a
specific pathway for processing and transport by compartmen-
talization and/or choice of proteins that are associated with the
transcript. If preferences for pol II transcripts are exerted at
different levels (processing, nuclear transport and export, ribo-
some binding, etc.) the combined effect may be sufficient to
effectively preclude mRNA synthesis by other polymerases. On
the other hand, it is possible that circumstances exist—for
example, during selected stages of development or phases of
the cell cycle or in unusual physiological states or virus infec-
tions—under which the pol II-coupled pathway of gene expres-
sion is inefficient or inactivated. Under such conditions, the
ability to generate mRNA by an alternative route might be
advantageous. This idea could explain the otherwise-surprising
observation that transcription from the adenovirus E2E pro-
moter (28, 54), c-myc P1 and P2 promoters (4, 9), and human
T-cell lymphotrophic virus type 1 promoter (52) can be initi-
ated by both pol II and pol III from a common start site.
Furthermore, there might be conditions under which uncapped
mRNA is preferentially used for protein synthesis, for in-
stance, when cap-binding protein is limiting. Under such cir-
cumstances, those RNAs that can initiate without a cap could
be selectively translated.
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